Collectively, these studies underscore the diverse approaches and potential of nanocarriers in targeting NLRP3 inflammasome‐driven inflammation, particularly in conditions such as sepsis, and highlight promising therapeutic avenues for managing a variety of inflammatory disorders, like sepsis. Here, NLRP3 is linked to Sepsis.